|
1
|
Pasetto LM, D’Andrea MR, Rossi E and
Monfardini S: Oxaliplatin-related neurotoxicity: how and why? Crit
Rev Oncol Hematol. 59:159–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lammers T, Hennink WE and Storm G:
Tumour-targeted nanomedicines: principles and practice. Br J
Cancer. 99:392–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Michor FJ, Iwasa Y, Lengauer C and Nowak
MA: Dynamics of colorectal cancer. Semin Cancer Biol. 15:484–493.
2005. View Article : Google Scholar
|
|
4
|
Hong M, Zhu S, Jiang Y, Tang G and Pei Y:
Efficient tumor targeting of hydroxycamptothecin loaded PEGylated
niosomes modified with transferrin. J Control Release. 133:96–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hussain S, Plückthun A, Allen TM and
Zangemeister-Wittke U: Antitumor activity of an epithelial cell
adhesion molecule targeted nanovesicular drug delivery system. Mol
Cancer Ther. 6:3019–3027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pietrangeli A, Leandri M, Terzoli E,
Jandolo B and Garufi C: Persistence of high-dose
oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol.
56:13–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stern ST, Hall JB, Yu LL, Wood LJ,
Paciotti GF, Tamarkin L, Long SE and McNeil SE: Translational
considerations for cancer nanomedicine. J Control Release.
146:164–174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun W, Zou W, Huang G, Li A and Zhang N:
Pharmacokinetics and targeting property of TFu-loaded liposomes
with different sizes after intravenous and oral administration. J
Drug Target. 16:357–365. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Allen TM, Hansen C, Martin F, Redemann C
and Yau-Young A: Liposomes containing synthetic lipid derivatives
of poly(ethylene glycol) show prolonged circulation half-lives in
vivo. Biochim Biophys Acta. 1066:29–36. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klibanov AL, Maruyama K, Beckerleg AM,
Torchilin VP and Huang L: Activity of amphipathic poly(ethylene
glycol) 5000 to prolong the circulation time of liposomes depends
on the liposome size and is unfavorable for immunoliposome binding
to target. Biochim Biophys Acta. 1062:142–148. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsumura Y and Maeda H: A new concept for
macromolecular therapeutics in cancer chemotherapy: mechanism of
tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI
|
|
12
|
Hao Z and Mak TW: Type I and type II
pathways of fas-mediated apoptosis are differentially controlled by
XIAP. J Mol Cell Biol. 2:63–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo X, Budihardjo I, Zou H, Slaughter C
and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c
release from mitochondria in response to activation of cell surface
death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jaattela M and Tschopp J:
Caspase-independent cell death in T lymphocytes. Nat Immunol.
4:416–423. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walters J, Pop C, Scott FL, Drag M, Swartz
P, Mattos C, Salvesen GS and Clark AC: A constitutively active and
uninhibitable caspase-3 zymogen efficiently induces apoptosis.
Biochem J. 424:335–345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bortner DM and Rosenberg MP:
Overexpression of cyclin A in the mammary glands of transgenic mice
results in the induction of nuclear abnormalities and increased
apoptosis. Cell Growth Differ. 6:1579–1589. 1995.PubMed/NCBI
|
|
18
|
Owa T, Yoshino H, Yoshimatsu K and Nagasu
T: Cell cycle regulation in the Gl phase: a promising target for
the development of new chemotherapeutic anticancer agents. Curr Med
Chem. 8:1487–1503. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buolamwini JK: Cell cycle molecular
targets in hovel anticancer drug discovery. Curr Pharm Des.
6:379–392. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McDonald ER and El-Deiry WS: Cell cycle
control as a basis for cancer drug development. Int J Oncol.
16:871–886. 2000.PubMed/NCBI
|
|
21
|
Yang C, Liu HZ, Fu ZX and Lu WD:
Oxaliplatin long-circulating liposomes improved therapeutic index
of colorectal carcinoma. BMC Biotechnol. 11:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang C, Liu HZ, Lu WD and Fu ZX:
PEG-liposomal oxaliplatin potentialization of antitumor efficiency
in a nude mouse tumor-xenograft model of colorectal carcinoma.
Oncol Rep. 25:1621–1628. 2011.PubMed/NCBI
|
|
23
|
Jost PJ, Grabow S, Gray D, McKenzie MD,
Nachbur U, Huang DC, Bouillet P, Thomas HE, Borner C, Silke J, et
al: XIAP discriminates between type I and type II FAS-induced
apoptosis. Nature. 460:1035–1039. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Harikumar KB, Kunnumakkara AB, Ahn KS,
Anand P, Krishnan S, Guha S and Aggarwal BB: Modification of the
cysteine residues in IκBα kinase and NF-κB(p65) by xanthohumol
leads to suppression of NF-κB-regulated gene products and
potentiation of apoptosis in leukemia cells. Blood. 113:2003–2013.
2009.
|
|
25
|
Nobili S, Checcacci D, Filippelli F, Del
Buono S, Mazzocchi V, Mazzei T and Mini E: Bimonthly chemotherapy
with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic
acid in patients with metastatic colorectal cancer pretreated with
irinotecan- or oxaliplatin-based chemotherapy. J Chemother.
20:622–631. 2008. View Article : Google Scholar
|
|
26
|
Abizon D and Papahadjopoulos D: Liposome
formulations with prolonged circulation time in blood and enhanced
uptake by tumors. Proc Natl Acad Sci USA. 85:6949–6953. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gabizon AA: Stealth liposomes and tumor
targeting: a step further in the quest for the magic bullet. Clin
Cancer Res. 7:223–225. 2001.PubMed/NCBI
|
|
28
|
Zalipsky S, Brandeis E, Newman MS and
Woodle MC: Long circulating, cationic liposomes containing
amino-PEG-phosphatidylethanolamine. FEBS Lett. 53:71–74. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Panwar P, Pandey B, Lakhera PC and Singh
KP: Preparation, characterization, and in vitro release study of
albendazole-encapsulated nanosize liposomes. Int J Nanomed.
5:101–108. 2010.PubMed/NCBI
|
|
30
|
Goren D, Horowitz AT, Tzemach D, Tarshish
M, Zalipsky S and Gabizon A: Nuclear delivery of doxorubicin via
folate-targeted liposomes with bypass of multidrug-resistance
efflux pump. Clin Cancer Res. 6:1949–1957. 2000.PubMed/NCBI
|
|
31
|
Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie
C and Wei Y: BIM-mediated AKT phosphorylation is a key modulator of
arsenic trioxide-induced apoptosis in cisplatin-sensitive and
-resistant ovarian cancer cells. PLoS One. 6:e205862011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pramanik KC, Boreddy SR and Srivastava SK:
Role of mitochondrial electron transport chain complexes in
capsaicin mediated oxidative stress leading to apoptosis in
pancreatic cancer cells. PLoS One. 6:e201512011. View Article : Google Scholar
|
|
33
|
Hunter T and Pines J: Cyclins and cancer
II: Cyclin D and CDK inhibitors come of age. Cell. 79:573–582.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Santamaria D and Ortega S: Cyclins and
CDKS in development and cancer: lessons from genetically modified
mice. Front Biosci. 11:1164–1188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Viallard JF, Lacombe F, Belloc F,
Pellegrin JL and Reiffers J: Molecular mechanisms controlling the
cell cycle: fundamental aspects and implications for oncology.
Cancer Radiother. 5:109–129. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hsia DA, Tepper CG, Pochampalli MR, Hsia
EY, Izumiya C, Huerta SB, Wright ME, Chen HW, Kung HJ and Izumiya
Y: KDM8, a H3K36me2 histone demethylase that acts in the Cyclin A1
coding region to regulate cancer cell proliferation. Proc Natl Acad
Sci USA. 107:9671–9676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sun PC, Tzao C, Chen BH, Liu CW, Yu CP and
Jin JS: Suberoylanilide hydroxamic acid induces apoptosis and
sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci.
17:762010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tung JN, Chiang CC, Tsai YY, Chou YY, Yeh
KT, Lee H and Cheng YW: CyclinD1 protein expressed in pterygia is
associated with β-catenin protein localization. Mol Vis.
16:2733–2738. 2010.PubMed/NCBI
|
|
39
|
Prall OW, Sarcevic B, Musgrove EA, Watts
CK and Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2
during G1-S phase progression is accompanied by increased Cyclin D1
expression and decreased cyclin-dependent kinase inhibitor
association with cyclin E-Cdk2. J Biol Chem. 272:10882–10894. 1997.
View Article : Google Scholar
|
|
40
|
Zhu X, Ohtsubo M, Böhmer RM, Roberts JM
and Assoian RK: Adhesion-dependent cell cycle progression linked to
the expression of Cyclin D1, activation of cyclin E-cdk2, and
phosphorylation of the retinoblastoma protein. J Cell Biol.
33:391–403. 1996. View Article : Google Scholar : PubMed/NCBI
|
